| CTRI Number |
CTRI/2025/08/093833 [Registered on: 28/08/2025] Trial Registered Prospectively |
| Last Modified On: |
|
| Post Graduate Thesis |
No |
| Type of Trial |
PMS |
|
Type of Study
|
Other (Specify) [Cosmetics] |
| Study Design |
Single Arm Study |
|
Public Title of Study
|
Eye Stinging Potential of Purite Baby 3 in 1 TF010625 |
|
Scientific Title of Study
|
A Single Blind Clinical Study to evaluate the Eye Stinging Potential of Purite Baby 3 in 1 TF010625 on healthy human volunteers |
| Trial Acronym |
NIL |
|
Secondary IDs if Any
|
| Secondary ID |
Identifier |
| CCFT759 Version 1.0 dated 26 Jul 2025 |
Protocol Number |
|
|
Details of Principal Investigator or overall Trial Coordinator (multi-center study)
|
| Name |
Dr Ishika Gandhi |
| Designation |
Principal Investigator |
| Affiliation |
CCFT Laboratories |
| Address |
CCFT Laboratories, Mittal Group Building, 121-B Mansarovar Industrial Estate, Panchli, Baghpat Road
Meerut
UTTAR PRADESH
250005
India |
| Phone |
9258535734 |
| Fax |
|
| Email |
ishika02gandhi@gmail.com |
|
Details of Contact Person
Scientific Query
|
| Name |
Puneet Mittal |
| Designation |
Clinical Research Consultant |
| Affiliation |
CCFT Laboratories |
| Address |
CCFT Laboratories, Mittal Group Building, 121-B Mansarovar Industrial Estate, Panchli, Baghpat Road
Meerut
UTTAR PRADESH
250005
India |
| Phone |
08937015757 |
| Fax |
|
| Email |
puneetmittal@mgcts.org |
|
Details of Contact Person
Public Query
|
| Name |
Puneet Mittal |
| Designation |
Clinical Research Consultant |
| Affiliation |
CCFT Laboratories |
| Address |
CCFT Laboratories, Mittal Group Building, 121-B Mansarovar Industrial Estate, Panchli, Baghpat Road
UTTAR PRADESH
250005
India |
| Phone |
08937015757 |
| Fax |
|
| Email |
puneetmittal@mgcts.org |
|
|
Source of Monetary or Material Support
|
| CCFT Laboratories, Mittal Group Building, 121-B Mansarovar Industrial Estate, Panchli, Baghpat Road, Meerut, UTTAR PRADESH-250005 |
| Marico South East Asia Corporation, No. 3, Street No. 5, Song Than 1 Industrial Park, Di An Ward, Ho Chi Minh City, Viet Nam |
|
|
Primary Sponsor
|
| Name |
Marico South East Asia Corporation |
| Address |
No. 3, Street No. 5, Song Than 1 Industrial Park, Di An Ward, Ho Chi Minh City, Viet Nam |
| Type of Sponsor |
Pharmaceutical industry-Global |
|
|
Details of Secondary Sponsor
|
| Name |
Address |
| Not Applicable |
Not Applicable |
|
|
Countries of Recruitment
|
India |
|
Sites of Study
|
| No of Sites = 1 |
| Name of Principal
Investigator |
Name of Site |
Site Address |
Phone/Fax/Email |
| Dr Ishika Gandhi |
CCFT laboratories |
CCFT Laboratories, Mittal Group Building, 121-B Mansarovar Industrial Estate, Panchli, Baghpat Road
Meerut
UTTAR PRADESH |
9258535734
ishika02gandhi@gmail.com |
|
|
Details of Ethics Committee
|
| No of Ethics Committees= 1 |
| Name of Committee |
Approval Status |
| ARMHRC Institutional Ethics Committee |
Approved |
|
|
Regulatory Clearance Status from DCGI
|
|
|
Health Condition / Problems Studied
|
| Health Type |
Condition |
| Healthy Human Volunteers |
Not Applicable |
|
|
Intervention / Comparator Agent
|
| Type |
Name |
Details |
| Comparator Agent |
Not Applicable |
Not Applicable |
| Intervention |
Test Product: Purite Baby 3 in 1 TF010625 |
Purite Baby 3 in 1 TF010625, Route of Administration: Topical Duration: 1 hour Frequency: Once |
|
|
Inclusion Criteria
|
| Age From |
18.00 Year(s) |
| Age To |
65.00 Year(s) |
| Gender |
Both |
| Details |
1.Healthy males or females, 18 to 65 years with no medical conditions of the eyes as determined by the subjects medical history and confirmed by an ophthalmologist
2. Subjects not under any doctor care for ocular or peri orbital diseases
3. The subject will refrain from using contact lenses, any topical facial products, any eye
drops, false eyelashes, make up, over the counter products, or cosmetics on their eyes, eyelids, eyelashes, or the periorbital areas
of the face during the study. |
|
| ExclusionCriteria |
| Details |
1.Subjects who are pregnant, breast-feeding, or planning to become
pregnant during the study.
2.Have any evidence of systemic cancer, squamous cell carcinoma,
basal cell carcinoma, in the last 5 years, or any other confounding
skin condition.
3.Have any condition that, in the opinion of the investigator, would
confound the safety and/or efficacy assessments of the product.
4.Have participated in any interventional clinical trial in the previous
30 days.
5.Have a known sensitivity to any of the constituents of the test
product including sensitivities to cocoamidopropyl betaine, coumarin,
Aloe barbadensis etc.
6.Have used, are using, or are planning to use immunosuppressive
or immunomodulatory medication (i.e., biologics), including
corticosteroids.
7.Have a history of alcohol or illegal drug/substance abuse, or
suspected alcohol or illegal drug/substance abuse in the past 2
years. |
|
|
Method of Generating Random Sequence
|
Not Applicable |
|
Method of Concealment
|
Not Applicable |
|
Blinding/Masking
|
Open Label |
|
Primary Outcome
|
| Outcome |
TimePoints |
1. Change in Discomfort
2. Change in Lacrimation
3. Change in Conjunctival inflammation
4. Change in Cornea and iris inflammation |
Time Points t1min, t2min, t5min |
|
|
Secondary Outcome
|
| Outcome |
TimePoints |
| Not Applicable |
Not Applicable |
|
|
Target Sample Size
|
Total Sample Size="32"
Sample Size from India="32"
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" |
|
Phase of Trial
|
Post Marketing Surveillance |
|
Date of First Enrollment (India)
|
10/09/2025 |
| Date of Study Completion (India) |
Applicable only for Completed/Terminated trials |
| Date of First Enrollment (Global) |
Date Missing |
| Date of Study Completion (Global) |
Applicable only for Completed/Terminated trials |
|
Estimated Duration of Trial
|
Years="0"
Months="0"
Days="2" |
|
Recruitment Status of Trial (Global)
|
Not Applicable |
| Recruitment Status of Trial (India) |
Not Yet Recruiting |
|
Publication Details
|
N/A |
|
Individual Participant Data (IPD) Sharing Statement
|
Will individual participant data (IPD) be shared publicly (including data dictionaries)?
Response - NO
|
|
Brief Summary
|
In Visit 1/Day 0 Step 1: Firstly, the subject enrolls into the study as per inclusion and exclusion criteria Step 2: Assessment of the subject as per discussed above (refer to study design)
In Visit 2/ Day 1 To check the irritation potential of the Purite Baby 3 in 1 TF010625 |